BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
Want to see TSE:BCT full AI Analyst Report?
Total Valuation
BriaCell Therapeutics has a market cap or net worth of C$32.70M. The enterprise value is -C$22.79M.
Market CapC$32.70M
Enterprise Value-C$22.79M
Share Statistics
BriaCell Therapeutics has 7,250,487 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,250,487
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BriaCell Therapeutics’s return on equity (ROE) is -1.48 and return on invested capital (ROIC) is -155.30%.
Return on Equity (ROE)-1.48
Return on Assets (ROA)-1.23
Return on Invested Capital (ROIC)-155.30%
Return on Capital Employed (ROCE)-1.55
Revenue Per Employee0.00
Profits Per Employee-1.66M
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BriaCell Therapeutics is ―. BriaCell Therapeutics’s PEG ratio is -0.00364.
PE Ratio―
PS Ratio0.00
PB Ratio0.24
Price to Fair Value0.24
Price to FCF-0.15
Price to Operating Cash Flow-0.29
PEG Ratio-0.00364
Income Statement
In the last 12 months, BriaCell Therapeutics had revenue of 0.00 and earned -26.63M in profits. Earnings per share was -62.95.
Revenue0.00
Gross Profit-107.93K
Operating Income-27.54M
Pretax Income-26.88M
Net Income-26.63M
EBITDA-27.43M
Earnings Per Share (EPS)-62.95
Cash Flow
In the last 12 months, operating cash flow was -30.97M and capital expenditures 0.00, giving a free cash flow of -30.97M billion.
Operating Cash Flow-30.97M
Free Cash Flow-30.97M
Free Cash Flow per Share-4.27
Dividends & Yields
BriaCell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change-90.38%
50-Day Moving Average5.51
200-Day Moving Average9.70
Relative Strength Index (RSI)39.76
Average Volume (3m)3.11K
Important Dates
BriaCell Therapeutics upcoming earnings date is Jun 17, 2026, TBA (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateJun 17, 2026
Ex-Dividend Date―
Financial Position
BriaCell Therapeutics as a current ratio of 5.01, with Debt / Equity ratio of 0.00%
Current Ratio5.01
Quick Ratio5.01
Debt to Market Cap0.00
Net Debt to EBITDA0.38
Interest Coverage Ratio-735.71
Taxes
In the past 12 months, BriaCell Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BriaCell Therapeutics EV to EBITDA ratio is 0.27, with an EV/FCF ratio of 0.26.
EV to Sales0.00
EV to EBITDA0.27
EV to Free Cash Flow0.26
EV to Operating Cash Flow0.26
Balance Sheet
BriaCell Therapeutics has C$29.65M in cash and marketable securities with C$0.00 in debt, giving a net cash position of C$29.65M billion.
Cash & Marketable SecuritiesC$29.65M
Total DebtC$0.00
Net CashC$29.65M
Net Cash Per ShareC$4.09
Tangible Book Value Per ShareC$40.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for BriaCell Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast44.28%